Oklo stock tumbles as Financial Times scrutinizes valuation
Investing.com - Citizens has reiterated its Market Outperform rating on U.S. Physical Therapy (NYSE:USPH) with a price target of $113.00. The company, currently valued at $1.35 billion, has shown strong momentum with a 33% return over the past six months. According to InvestingPro data, the stock appears to be trading near its Fair Value.
The research firm expressed increasing conviction in USPH’s ability to extend its double-digit EBITDA growth rate into 2026.
Citizens continues to model 16% profit growth for the company in 2025, attributing this projection to payor re-contracting efforts, strong demand for physical therapy services, and the impact from accretive acquisitions.
The firm is focusing on several key areas including efficiency initiatives, M&A opportunities, and the growth of USPH’s home-based services.
Citizens is also monitoring management’s view of the Medicare rate backdrop beyond 2027 as part of its analysis of the physical therapy provider’s long-term prospects.
In other recent news, U.S. Physical Therapy reported strong second-quarter 2025 financial results, exceeding analyst expectations. The company achieved an earnings per share (EPS) of $0.81, surpassing the projected $0.70, which represents a 15.71% surprise. Revenue also outperformed forecasts, reaching $197.34 million compared to the anticipated $189.66 million. These results reflect positively on the company’s financial health and operational performance. Additionally, JPMorgan has initiated coverage of U.S. Physical Therapy with an Overweight rating, setting a price target of $110.00. The investment bank highlights the company’s strategic positioning to benefit from long-term demographic trends, such as an aging population and increased demand for physical therapy services. These developments are important for investors to consider in their assessments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.